Immune markers and correlates of protection for vaccine induced immune responses

Vaccine

Volumn 30, Issue 33, 2012, Pages 4907-4920

  Thakur, Aneesh ^a   Pedersen, Lasse E ^a   Jungersen, Gregers ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Chronic infections; Correlates of protection; Vaccines

Indexed keywords

ATTENUAVAX; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPLOID CELL VACCINE; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MMRII; MUMPS VACCINE; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; POLIOVAX; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HAEMOPHILUS INFECTION; HELPER CELL; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFLUENZA; JAPANESE ENCEPHALITIS; MEASLES; MEMORY CELL; MEMORY T LYMPHOCYTE; MENINGOCOCCOSIS; MUMPS; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; ROTAVIRUS INFECTION; RUBELLA; SMALLPOX; TH1 CELL; TUBERCULOSIS; VACCINATION; YELLOW FEVER;

ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; LYMPHOCYTES; VACCINES;

EID: 84862761006     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.049     Document Type: Review

References (241)

1. FDA. Guidance for industry: for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. US Department of Health and Human Services, food and Drug Administration, Center for Biologics Evaluation and Research; 1997 January Report No.: 97N-0029.
2. Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012.
3. Schodel F. Immunological correlates of vaccine-derived protection fondation merieux conference center 'les pensieres' Veyrier-du-lac, France, Sept. 20-22, 2010. Vaccine 2011, 29:9575-9577.
4. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004, 1:189-195.
5. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236.
6. Kaufmann S.H. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007, 5:491-504.
7. Moore T., Ekworomadu C.O., Eko F.O., MacMillan L., Ramey K., Ananaba G.A., et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003, 188:617-624.
8. Moore A.C., Hutchings C.L. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 2007, 6:111-121.
9. McManus D.P., Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008, 21:225-242.
10. Plotkin S.A. Vaccination against the major infectious diseases. CR Acad Sci III 1999, 322:943-951.
11. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20:63-75.
12. Igietseme J.U., Eko F.O., He Q., Black C.M. Antibody regulation of T cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004, 3:23-34.
13. Joller N., Weber S.S., Oxenius A. Antibody-Fc receptor interactions in protection against intracellular pathogens. Eur J Immunol 2011, 41:889-897.
14. Siegrist C.A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier-Saunders, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
15. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
16. Sarkar J.K., Mitra A.C., Mukherjee M.K. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
17. Mack T.M., Noble J., Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
18. Mason R.A., Tauraso N.M., Spertzel R.O., Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973, 25:539-544.
19. Donati M., Di F.A., Delucca F., Di P.M., Battilani M., Balboni A., et al. Antibody-neutralizing activity against all urogenital Chlamydia trachomatis serovars in Chlamydia suis-infected pigs. FEMS Immunol Med Microbiol 2011, 61:125-128.
20. Su H., Parnell M., Caldwell H.D. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 1995, 13:1023-1032.
21. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182:8063-8070.
22. Li W., Murthy A.K., Guentzel M.N., Chambers J.P., Forsthuber T.G., Seshu J., et al. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun 2010, 78:3942-3949.
23. Schofield L., Vivas L., Hackett F., Gerold P., Schwarz R.T., Tachado S. Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of Plasmodium falciparum: prospects for the immunotherapy of severe malaria. Ann Trop Med Parasitol 1993, 87:617-626.
24. Lazarou M., Guevara Patino J.A., Jennings R.M., McIntosh R.S., Shi J., Howell S., et al. Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies. Infect Immun 2009, 77:5659-5667.
25. Iriemenam N.C., Khirelsied A.H., Nasr A., ElGhazali G., Giha H.A., Elhassan A.-E., et al. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 2009, 27:62-71.
26. Williams A., Reljic R., Naylor I., Clark S.O., Falero-Diaz G., Singh M., et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004, 111:328-333.
27. Glatman-Freedman A. Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy. FEMS Immunol Med Microbiol 2003, 39:9-16.
28. Corey M.J., Kinders R.J., Brown L.G., Vessella R.L. A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. J Immunol Methods 1997, 207:43-51.
29. Cho M.H., Niles A., Huang R., Inglese J., Austin C.P., Riss T., et al. A bioluminescent cytotoxicity assay for assessment of membrane integrity using a proteolytic biomarker. Toxicol In Vitro 2008, 22:1099-1106.
30. Ahmad A., Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996, 10:258-266.
31. Gomez-Roman V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005, 174:2185-2189.
32. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005, 23:2522-2529.
33. Jegerlehner A., Schmitz N., Storni T., Influenza Bachmann M.F. A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
34. Jafarshad A., Dziegiel M.H., Lundquist R., Nielsen L.K., Singh S., Druilhe P.L. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 2007, 178:3099-3106.
35. Moore T., Ananaba G.A., Bolier J., Bowers S., Belay T., Eko F.O., et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 2002, 105:213-221.
36. Woelbing F., Kostka S.L., Moelle K., Belkaid Y., Sunderkoetter C., Verbeek S., et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 2006, 203:177-188.
37. Maglione P.J., Xu J., Casadevall A., Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008, 180:3329-3338.
38. Plotkin S.A., Vidor E. Poliovirus vaccine-inactivated. Vaccines 2008, 605-630. Elsevier-Saunders, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, W.A. Offit (Eds.).
39. Lee C.J., Lee L.H., Gu X.X. Mucosal immunity induced by pneumococcal glycoconjugate. Crit Rev Microbiol 2005, 31:137-144.
40. Zhang Q., Choo S., Everard J., Jennings R., Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000, 68:2692-2697.
41. Le T.V., Mironova E., Garcin D., Compans R.W. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One 2011, 6:e18780.
42. Garcia-Diaz A., Lopez-Andujar P., Rodriguez D.J., Montava R., Torres B.C., Ribes J.M., et al. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies. Vaccine 2004, 23:489-498.
43. Azevedo M.S., Yuan L., Iosef C., Chang K.O., Kim Y., Nguyen T.V., et al. Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. Clin Diagn Lab Immunol 2004, 11:12-20.
44. Torrieri-Dramard L., Lambrecht B., Ferreira H.L., Van den B.T., Klatzmann D., Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther 2011, 19:602-611.
45. Baron S.D., Singh R., Metzger D.W. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 2007, 75:2152-2162.
46. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
47. Gilbert P., Wang M., Wrin T., Petropoulos C., Gurwith M., Sinangil F., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202:595-605.
48. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-4973.
49. Liao S.S., Li R.C., Li H., Yang J.Y., Zeng X.J., Gong J., et al. Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children: a 12-year follow-up study. World J Gastroenterol 1999, 5:165-166.
50. Tuaillon E., Tabaa Y.A., Petitjean G., Huguet M.F., Pajeaux G., Fondere J.M., et al. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods 2006, 315:144-152.
51. Jego G., Robillard N., Puthier D., Amiot M., Accard F., Pineau D., et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999, 94:701-712.
52. Longwe H., Gordon S., Malamba R., French N. Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults. BMC Infect Dis 2010, 10:280.
53. Lin Y.C., Chang M.H., Ni Y.H., Hsu H.Y., Chen D.S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003, 187:134-138.
54. Young B.W., Lee S.S., Lim W.L., Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 2003, 10:23-30.
55. Rojas O.L., Caicedo L., Guzman C., Rodriguez L.S., Castaneda J., Uribe L., et al. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol 2007, 20:300-311.
56. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
57. Leyendeckers H., Odendahl M., Lohndorf A., Irsch J., Spangfort M., Miltenyi S., et al. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 1999, 29:1406-1417.
58. Klenovsek K., Weisel F., Schneider A., Appelt U., Jonjic S., Messerle M., et al. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007, 110:3472-3479.
59. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
60. Comstock G.W. Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 1994, 15:247-276.
61. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300:337-339.
62. Sun J.C., Williams M.A., Bevan M.J.C.D4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004, 5:927-933.
63. Hutchings P.R., Cambridge G., Tite J.P., Meager T., Cooke A. The detection and enumeration of cytokine-secreting cells in mice and man and the clinical application of these assays. J Immunol Methods 1989, 120:1-8.
64. De P.R., Chou A.Y., Bosio C.M., Huang C.Y., Follmann D.A., Elkins K.L. Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen F. tularensis LVS. PLoS Pathog 2012, 8:e1002494.
65. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005, 175:5675-5680.
66. Streeck H., Frahm N., Walker B.D. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009, 4:461-469.
67. Buddle B.M., Wedlock D.N., Denis M., Skinner M.A. Identification of immune response correlates for protection against bovine tuberculosis. Vet Immunol Immunopathol 2005, 108:45-51.
68. Mwacharo J., Dunachie S.J., Kai O., Hill A.V., Bejon P., Fletcher H.A. evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine. PLoS One 2009, 4:e8434.
69. Dunachie S.J., Berthoud T., Keating S.M., Hill A.V., Fletcher H.A. MIG and the regulatory cytokines IL-10 and TGF-beta1 correlate with malaria vaccine immunogenicity and efficacy. PLoS One 2010, 5:e12557.
70. Fulcher D., Wong S. Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory. Immunol Cell Biol 1999, 77:559-564.
71. Perfetto S.P., Chattopadhyay P.K., Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004, 4:648-655.
72. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
73. De Rosa S.C., Lu F.X., Yu J., Perfetto S.P., Falloon J., Moser S., et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004, 173:5372-5380.
74. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
75. Lumsden J.M., Schwenk R.J., Rein L.E., Moris P., Janssens M., Ofori-Anyinam O., et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-alpha producing effector and central memory CD4T cells. PLoS One 2011, 6:e20775.
76. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
77. Hope J.C., Thom M.L., McAulay M., Mead E., Vordermeier H.M., Clifford D., et al. Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish. Clin Vaccine Immunol 2011, 18:373-379.
78. Sopp P., Howard C.J., Hope J.C. Flow cytometric detection of gamma interferon can effectively discriminate Mycobacterium bovis BCG-vaccinated cattle from M. bovis-infected cattle. Clin Vaccine Immunol 2006, 13:1343-1348.
79. Burgers W.A., Chege G.K., Muller T.L., van Harmelen J.H., Khoury G., Shephard E.G., et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009, 90:468-480.
80. Cassataro J., Velikovsky C.A., de la B.S., Estein S.M., Bruno L., Bowden R., et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 2005, 73:6537-6546.
81. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
82. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178:2249-2254.
83. Paranavitana C., Zelazowska E., Izadjoo M., Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine 2005, 30:86-92.
84. Kawamura I., Tsukada H., Yoshikawa H., Fujita M., Nomoto K., Mitsuyama M. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice. J Immunol 1992, 148:2887-2893.
85. Li W., Murthy A.K., Guentzel M.N., Seshu J., Forsthuber T.G., Zhong G., et al. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol 2008, 180:3375-3382.
86. Parida S., Oh Y., Reid S.M., Cox S.J., Statham R.J., Mahapatra M., et al. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 2006, 24:964-969.
87. Madariaga M.G., Jalali Z., Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med 2007, 20:540-547.
88. Mazurek G.H., Villarino M.E. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52:15-18.
89. McElhaney J.E., Ewen C., Zhou X., Kane K.P., Xie D., Hager W.D., et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009, 27:2418-2425.
90. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
91. Snydman D.R. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001, 3:6-13.
92. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
93. Mittrucker H.W., Steinhoff U., Kohler A., Krause M., Lazar D., Mex P., et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007, 104:12434-12439.
94. Caruso A.M., Serbina N., Klein E., Triebold K., Bloom B.R., Flynn J.L. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999, 162:5407-5416.
95. Majlessi L., Simsova M., Jarvis Z., Brodin P., Rojas M.J., Bauche C., et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006, 74:2128-2137.
96. Lambert P.H., Hawkridge T., Hanekom WA New vaccines against tuberculosis. Clin Chest Med 2009, 30:811-826.
97. Kagina B.M., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
98. Gallegos A.M., van Heijst J.W., Samstein M., Su X., Pamer E.G., Glickman M.S. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011, 7:e1002052.
99. Bold T.D., Banaei N., Wolf A.J., Ernst J.D. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog 2011, 7:e1002063.
100. Elias D., Akuffo H., Britton S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2005, 99:363-368.
101. Gicheru M.M., Olobo J.O., Anjili C.O., Orago A.S., Modabber F., Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001, 69:245-251.
102. Blackwell J.M. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 1996, 112:S67-S74.
103. Bloom B.R., Flynn J., McDonough K., Kress Y., Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 1994, 191:526-536.
104. Williams M.A., Holmes B.J., Sun J.C., Bevan M.J. Developing and maintaining protective CD8+ memory T cells. Immunol Rev 2006, June (211):146-153.
105. Nussler A., Drapier J.C., Renia L., Pied S., Miltgen F., Gentilini M., et al. L-arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. Eur J Immunol 1991, 21:227-230.
106. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
107. Mastroeni P., Villarreal-Ramos B., Hormaeche C.E. Role of T cells, TNF alpha and IFN gamma in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro-Salmonella vaccines. Microb Pathog 1992, 13:477-491.
108. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989, 143:2894-2899.
109. Blanchard D.K., Michelini-Norris M.B., Friedman H., Djeu J.Y. Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1. Cell Immunol 1989, 119:402-411.
110. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169:6376-6385.
111. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
112. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
113. Olsen A.W., Theisen M., Christensen D., Follmann F., Andersen P. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 2010, 5:e10768.
114. Rosa D.S., Ribeiro S.P., Almeida R.R., Mairena E.C., Postol E., Kalil J., et al. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One 2011, 6:e16921.
115. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
116. Bai H., Cheng J., Gao X., Joyee A.G., Fan Y., Wang S., et al. IL-17/Th17 promotes type 1T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009, 183:5886-5895.
117. Lin Y., Ritchea S., Logar A., Slight S., Messmer M., Rangel-Moreno J., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31:799-810.
118. Okamoto Y.Y., Umemura M., Yahagi A., O'Brien R.L., Ikuta K., Kishihara K., et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010, 184:4414-4422.
119. Hamada S., Umemura M., Shiono T., Tanaka K., Yahagi A., Begum M.D., et al. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. J Immunol 2008, 181:3456-3463.
120. Meeks K.D., Sieve A.N., Kolls J.K., Ghilardi N., Berg R.E. IL-23 is required for protection against systemic infection with Listeria monocytogenes. J Immunol 2009, 183:8026-8034.
121. Torrado E., Cooper A.M. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010, 21:455-462.
122. Smith S.G., Lalor M.K., Gorak-Stolinska P., Blitz R., Beveridge N.E., Worth A., et al. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 2010, 11:35.
123. Ahmed R.K., Makitalo B., Karlen K., Nilsson C., Biberfeld G., Thorstensson R. Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol 2002, 129:11-18.
124. Casazza J.P., Brenchley J.M., Hill B.J., Ayana R., Ambrozak D., Roederer M., et al. Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection. PLoS Pathog 2009, 5:e1000646.
125. Song R., Liu S., Leong K.W. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther 2007, 15:1007-1015.
126. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., Heyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
127. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998, 188:1641-1650.
128. Dunbar P.R., Ogg G.S., Chen J., Rust N., van der B.P., Cerundolo V. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998, 8:413-416.
129. Leisner C., Loeth N., Lamberth K., Justesen S., Sylvester-Hvid C., Schmidt E.G., et al. One-pot, mix-and-read peptide-MHC tetramers. PLoS One 2008, 3:e1678.
130. Sylvester-Hvid C., Kristensen N., Blicher T., Ferre H., Lauemoller S.L., Wolf X.A., et al. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. Tissue Antigens 2002, 59:251-258.
131. Malyguine A., Strobl S., Zaritskaya L., Baseler M., Shafer-Weaver K. New approaches for monitoring CTL activity in clinical trials. Adv Exp Med Biol 2007, 601:273-284.
132. Pedersen L.E., Harndahl M., Rasmussen M., Lamberth K., Golde W.T., Lund O., et al. Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities. Immunogenetics 2012, 63:821-834.
133. Choi E.M., Palmowski M., Chen J., Cerundolo V. The use of chimeric A2K(b) tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice. J Immunol Methods 2002, 268:35-41.
134. Patch J.R., Pedersen L.E., Toka F.N., Moraes M., Grubman M.J., Nielsen M., et al. Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination. Clin Vaccine Immunol 2011, 18:280-288.
135. Zuber B., Levitsky V., Jonsson G., Paulie S., Samarina A., Grundstrom S., et al. Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J Immunol Methods 2005, 302:13-25.
136. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
137. Guzman E., Taylor G., Charleston B., Skinner M.A., Ellis S.A. An MHC-restricted CD8+ T-cell response is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV. J Gen Virol 2008, 89:667-675.
138. Marinaro M., Tempesta M., Tarsitano E., Camero M., Losurdo M., Buonavoglia C., Rezza G. Antigen-specific IFN-gamma and IL-4 production in caprine herpesvirus infected goats. Res Vet Sci 2011, 10.1016/j.rvsc.2011.09.009.
139. Wang X., Chan C.C., Yang M., Deng J., Poon V.K., Leung V.H., et al. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. Immunology 2011, 132:482-491.
140. Romero P., Cerottini J.C., Speiser D.E. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004, 53:249-255.
141. Altman JD, Davis MM. MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc Immunol, May 2003 [chapter 17:unit].
142. Wooldridge L., Lissina A., Cole D.K., van den Berg H.A., Price D.A., Sewell A.K. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009, 126:147-164.
143. Xu X.N., Screaton G.R. MHC/peptide tetramer-based studies of T cell function. J Immunol Methods 2002, 268:21-28.
144. Schmidt E.G., Buus S., Thorn M., Stryhn A., Leisner C., Claesson M.H. Peptide specific expansion of CD8(+) T cells by recombinant plate bound MHC/peptide complexes. J Immunol Methods 2009, 340:25-32.
145. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432:769-775.
146. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
147. thor Straten P., Kirkin A.F., Siim E., Dahlstrom K., Drzewiecki K.T., Seremet T., et al. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol 2000, 96:94-99.
148. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
149. Ballesteros-Tato A., Randall T.D. Memory: the incomplete unhappening of differentiation. Immunity 2011, 35:496-498.
150. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
151. Amara R.R., Nigam P., Sharma S., Liu J., Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8T cells. J Virol 2004, 78:3811-3816.
152. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
153. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
154. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003, 4:835-842.
155. Vaccari M., Trindade C.J., Venzon D., Zanetti M., Franchini G. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immunol 2005, 175:3502-3507.
156. Castiglioni P., Hall dS, Jacovetty E.L., Ingulli E., Zanetti M. Protection against influenza A virus by memory CD8 T cells requires reactivation by bone marrow-derived dendritic cells. J Immunol 2008, 180:4956-4964.
157. Scheller L.F., Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995, 92:4066-4068.
158. Uzonna J.E., Wei G., Yurkowski D., Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 2001, 167:6967-6974.
159. Dudani R., Chapdelaine Y., Faassen H.H., Smith D.K., Shen H., Krishnan L., et al. Multiple mechanisms compensate to enhance tumor-protective CD8(+) T cell response in the long-term despite poor CD8(+) T cell priming initially: comparison between an acute versus a chronic intracellular bacterium expressing a model antigen. J Immunol 2002, 168:5737-5745.
160. Kaveh D.A., Bachy V.S., Hewinson R.G., Hogarth P.J. Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T(EM) cells which expand following virulent mycobacterial challenge. PLoS One 2011, 6:e21566.
161. Berchtold C., Panthel K., Jellbauer S., Kohn B., Roider E., Partilla M., et al. Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium. Infect Immun 2009, 77:5501-5508.
162. Puissant-Lubrano B., Bossi P., Gay F., Crance J.M., Bonduelle O., Garin D., et al. Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+effector/memory CD4+ lymphocytes in humans. J Clin Invest 2010, 120:1636-1644.
163. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011, 187:1347-1357.
164. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
165. Duvall M.G., Precopio M.L., Ambrozak D.A., Jaye A., McMichael A.J., Whittle H.C., et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008, 38:350-363.
166. Draper S.J., Biswas S., Spencer A.J., Remarque E.J., Capone S., Naddeo M., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 2010, 185:7583-7595.
167. Salerno-Goncalves R., Wahid R., Sztein M.B. Ex Vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine. Clin Vaccine Immunol 2010, 17:1305-1314.
168. Derrick S.C., Yabe I.M., Yang A., Morris S.L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011, 29:2902-2909.
169. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 2009, 4:e5930.
170. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007, 37:3089-3100.
171. Aagaard C.S., Hoang T.T., Vingsbo-Lundberg C., Dietrich J., Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009, 183:2659-2668.
172. Bansal A., Jackson B., West K., Wang S., Lu S., Kennedy J.S., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82:6458-6469.
173. Kolibab K., Yang A., Derrick S.C., Waldmann T.A., Perera L.P., Morris S.L. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 2010, 17:793-801.
174. Pueschel K., Tietz A., Carsillo M., Steward M., Niewiesk S. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. J Virol 2007, 81:8571-8578.
175. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu C., Zhou D., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005, 434:525-529.
176. Sada-Ovalle I., Chiba A., Gonzales A., Brenner M.B., Behar S.M. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 2008, 4:e1000239.
177. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 2007, 104:3984-3989.
178. Dondji B., Deak E., Goldsmith-Pestana K., Perez-Jimenez E., Esteban M., Miyake S., et al. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 2008, 38:706-719.
179. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009, 106:3330-3335.
180. Hiromatsu K., Yoshikai Y., Matsuzaki G., Ohga S., Muramori K., Matsumoto K., et al. A protective role of gamma/delta T cells in primary infection with Listeria monocytogenes in mice. J Exp Med 1992, 175:49-56.
181. King D.P., Hyde D.M., Jackson K.A., Novosad D.M., Ellis T.N., Putney L., et al. Cutting edge: protective response to pulmonary injury requires gamma delta T lymphocytes. J Immunol 1999, 162:5033-5036.
182. Wilson R.A., Zolnai A., Rudas P., Frenyo L.V. T-cell subsets in blood and lymphoid tissues obtained from fetal calves, maturing calves, and adult bovine. Vet Immunol Immunopathol 1996, 53:49-60.
183. Yang H., Parkhouse R.M. Characterization of the porcine gammadelta T-cell receptor structure and cellular distribution by monoclonal antibody PPT27. Immunology 2000, 99:504-509.
184. Yang H., Parkhouse R.M. Phenotypic classification of porcine lymphocyte subpopulations in blood and lymphoid tissues. Immunology 1996, 89:76-83.
185. Siddiqui N., Price S., Hope J. BCG vaccination of neonatal calves: Potential roles for innate immune cells in the induction of protective immunity. Comp Immunol Microbiol Infect Dis 2012, 35:219-226.
186. Wang T., Gao Y., Scully E., Davis C.T., Anderson J.F., Welte T., et al. Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. J Immunol 2006, 177:1825-1832.
187. Lehner T., Mitchell E., Bergmeier L., Singh M., Spallek R., Cranage M., et al. The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000, 30:2245-2256.
188. Berndt A., Gamma/delta Methner U. T cell response of chickens after oral administration of attenuated and non-attenuated Salmonella typhimurium strains. Vet Immunol Immunopathol 2001, 78:143-161.
189. Price S., Davies M., Villarreal-Ramos B., Hope J. Differential distribution of WC1(+) gammadelta TCR(+) T lymphocyte subsets within lymphoid tissues of the head and respiratory tract and effects of intranasal M. bovis BCG vaccination. Vet Immunol Immunopathol 2010, 136:133-137.
190. Tenner-Racz K., Stahl H.C., Uberla K., Stoiber H., Ignatius R., Heeney J., et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 2004, 101:3017-3022.
191. Pintaric M., Gerner W., Saalmuller A. Synergistic effects of IL-2, IL-12 and IL-18 on cytolytic activity, perforin expression and IFN-gamma production of porcine natural killer cells. Vet Immunol Immunopathol 2008, 121:68-82.
192. Begg D., Plain K., De Silva K., Purdie A., Whittington R. Extension of the storage time of blood in interferon gamma assays to diagnose paratuberculosis: combination of IL-7 and IL-12 stimulation. Proceedings of the 11th International Colloquium on Paratuberculosis; 2012 Feb 5-10 2012, International Association for Paratuberculosis, p. 6. S.S. Nielsen (Ed.).
193. Collins R.A., Howard C.J., Duggan S.E., Werling D. Bovine interleukin-12 and modulation of IFNgamma production. Vet Immunol Immunopathol 1999, 68:193-207.
194. Jungersen G., Mikkelsen H., Grell S.N. Use of the johnin PPD interferon-gamma assay in control of bovine paratuberculosis. Vet Immunol Immunopathol 2011, 10.1016/j.vetimm.2011.05.010.
195. Riber U., Boesen H.T., Jakobsen J.T., Nguyen L.T., Jungersen G. Co-incubation with IL-18 potentiates antigen-specific IFN-gamma response in a whole-blood stimulation assay for measurement of cell-mediated immune responses in pigs experimentally infected with Lawsonia intracellularis. Vet Immunol Immunopathol 2011, 139:257-263.
196. Platt R., Thoen C.O., Stalberger R.J., Chiang Y.W., Roth J.A. Evaluation of the cell-mediated immune response to reduced doses of Mycobacterium avium ssp. paratuberculosis vaccine in cattle. Vet Immunol Immunopathol 2010, 136:122-126.
197. Gerner W., Kaser T., Pintaric M., Groiss S., Saalmuller A. Detection of intracellular antigens in porcine PBMC by flow cytometry: A comparison of fixation and permeabilisation reagents. Vet Immunol Immunopathol 2008, 121:251-259.
198. Gomez-Laguna J., Salguero F.J., De Marco M.F., Pallares F.J., Bernabe A., Carrasco L. Changes in lymphocyte subsets and cytokines during European porcine reproductive and respiratory syndrome: increased expression of IL-12 and IL-10 and proliferation of CD4(-)CD8(high). Viral Immunol 2009, 22:261-271.
199. Whelan A.O., Villarreal-Ramos B., Vordermeier H.M., Hogarth P.J. Development of an antibody to bovine IL-2 reveals multifunctional CD4 T(EM) cells in cattle naturally infected with Bovine Tuberculosis. PLoS One 2011, 6:e29194.
200. Waters W.R., Nonnecke B.J., Foote M.R., Maue A.C., Rahner T.E., Palmer M.V., et al. Mycobacterium bovis bacille Calmette-Guerin vaccination of cattle: activation of bovine CD4+ and gamma delta TCR+ cells and modulation by 1,25-dihydroxyvitamin D3. Tuberculosis (Edinburgh) 2003, 83:287-297.
201. Peng Y.T., Chaung H.C., Chang H.L., Chang H.C., Chung W.B. Modulations of phenotype and cytokine expression of porcine bone marrow-derived dendritic cells by porcine reproductive and respiratory syndrome virus. Vet Microbiol 2009, 136:359-365.
202. Shooshtari P., Fortuno E.S., Blimkie D., Yu M., Gupta A., Kollmann T.R., et al. Correlation analysis of intracellular and secreted cytokines via the generalized integrated mean fluorescence intensity. Cytometry A 2010, 77:873-880.
203. Ferre H., Ruffet E., Blicher T., Sylvester-Hvid C., Nielsen L.L., Hobley T.J., et al. Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: a novel strategy exploiting disulfide assisted protein folding. Protein Sci 2003, 12:551-559.
204. Harndahl M., Justesen S., Lamberth K., Roder G., Nielsen M., Buus S. Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen 2009, 14:173-180.
205. Ostergaard P.L., Nissen M.H., Hansen N.J., Nielsen L.L., Lauenmoller S.L., Blicher T., et al. Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol 2001, 31:2986-2996.
206. Pedersen L.O., Stryhn A., Holter T.L., Etzerodt M., Gerwien J., Nissen M.H., et al. The interaction of beta 2-microglobulin (beta 2 m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur J Immunol 1995, 25:1609-1616.
207. Stryhn A., Pedersen L.O., Romme T., Holm C.B., Holm A., Buus S. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur J Immunol 1996, 26:1911-1918.
208. Hoof I., Peters B., Sidney J., Pedersen L.E., Sette A., Lund O., et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009, 61:1-13.
209. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Brunak S., Lund O., et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005, 35:2295-2303.
210. Lundegaard C., Lund O., Nielsen M. Prediction of epitopes using neural network based methods. J Immunol Methods 2011, 374:26-34.
211. Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007, 2:e796.
212. Pedersen LE, Harndahl M, Nielsen M, Patch JR, Jungersen G, Buus S, et al. Identification of peptides from foot-and-mouth disease virus structural proteins bound by class I swine leucocyte antigen (SLA) alleles, SLA-1*0401 and SLA-2*0401. Anim Gen 2012; accepted for publication.
213. Nene V, Svitek N, Toye P, Golde WT, Barlow J, Buus S, et al. Designing bovine T cell vaccines via reverse immunology. Ticks Tick-borne Dis; 2012, . doi:10.1016/j.ttbdis.2011.12.001.
214. Buus S. Description and prediction of peptide-MHC binding: the 'human MHC project'. Curr Opin Immunol 1999, 11:209-213.
215. Horton R., Das P. The vaccine paradox. Lancet 2011, 378:296-298.
216. Haralambieva I.H., Poland G.A. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol 2010, 5:1757-1760.
217. Kitano H. Computational systems biology. Nature 2002, 420:206-210.
218. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
219. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
220. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
221. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990, 162:1036-1042.
222. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995, 14:203-209.
223. Weibel R.E., Buynak E.B., McLean A.A., Hilleman M.R. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 1975, 56:380-387.
224. Nalin D.R., Kuter B.J., Brown L., Patterson C., Calandra G.B., Werzberger A., et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993, 18:S51-S55.
225. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179:489-492.
226. Dowdle W.R., Coleman M.T., Mostow S.R., Kaye H.S., Schoenbaum S.C. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 1973, 49:159-163.
227. Matter L., Kogelschatz K., Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 1997, 175:749-755.
228. Maslanka S.E., Tappero J.W., Plikaytis B.D., Brumberg R.S., Dykes J.K., Gheesling L.L., et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998, 66:2453-2459.
229. Franco M.A., Angel J., Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731.
230. Schiller J.T., Frazer I.H., Lowy D.R. Human papillomavirus vaccines. Vaccines 2008, 243-258. Elsevier-Saunders, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
231. Fletcher H.A. Correlates of immune protection from tuberculosis. Curr Mol Med 2007, 7:319-325.
232. Doherty T.M., Demissie A., Olobo J., Wolday D., Britton S., Eguale T., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002, 40:704-706.
233. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005, 175:788-795.
234. Fjore A.E., Finestone S.M., Bell B.P. Hepatitis A vaccine. Vaccines 2008, 177-203. Elsevier-Saunders, Philadelphia,PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
235. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983, 147:1100.
236. Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994, 22:397-402.
237. Rabies vaccines WHO position paper. Wkly Epidemiol Rec 2007, 82:425-435.
238. Skendzel L.P. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996, 106:170-174.
239. Li S., Chan I.S., Matthews H., Heyse J.F., Chan C.Y., Kuter B.J., et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002, 21:337-342.
240. White C.J., Kuter B.J., Ngai A., Hildebrand C.S., Isganitis K.L., Patterson C.M., et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992, 11:19-23.
241. Weinberg A., Zhang J.H., Oxman M.N., Johnson G.R., Hayward A.R., Caulfield M.J., et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009, 200:1068-1077.